Ernst Ulbrich

1.1k total citations
24 papers, 824 citations indexed

About

Ernst Ulbrich is a scholar working on Psychiatry and Mental health, Clinical Psychology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Ernst Ulbrich has authored 24 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 10 papers in Clinical Psychology and 9 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Ernst Ulbrich's work include Sexual function and dysfunction studies (18 papers), Sexuality, Behavior, and Technology (10 papers) and Hormonal and reproductive studies (9 papers). Ernst Ulbrich is often cited by papers focused on Sexual function and dysfunction studies (18 papers), Sexuality, Behavior, and Technology (10 papers) and Hormonal and reproductive studies (9 papers). Ernst Ulbrich collaborates with scholars based in Germany, United States and Australia. Ernst Ulbrich's co-authors include Manfred Beneke, Christian G. Stief, Hartmut Porst, H. Porst, D. Neuser, Harin Padma-Nathan, François Giuliano, R. Rosen, Irwin Goldstein and I Sáenz de Tejada and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, The Journal of Urology and European Urology.

In The Last Decade

Ernst Ulbrich

22 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ernst Ulbrich Germany 13 652 471 347 189 108 24 824
C C Carson United States 13 531 0.8× 253 0.5× 221 0.6× 196 1.0× 48 0.4× 23 813
Fisseha Tesfaye United States 11 663 1.0× 162 0.3× 321 0.9× 375 2.0× 88 0.8× 22 787
Richard Casey Canada 15 213 0.3× 234 0.5× 309 0.9× 81 0.4× 31 0.3× 41 721
Leslie Todd United States 6 422 0.6× 344 0.7× 220 0.6× 94 0.5× 26 0.2× 11 551
Giuseppe Pera Italy 11 494 0.8× 298 0.6× 233 0.7× 199 1.1× 77 0.7× 34 1.0k
Giulia Castagna Italy 12 277 0.4× 241 0.5× 108 0.3× 96 0.5× 24 0.2× 20 519
Yiming Yuan China 16 326 0.5× 139 0.3× 146 0.4× 142 0.8× 27 0.3× 69 794
Theodor Klotz Germany 16 274 0.4× 212 0.5× 247 0.7× 50 0.3× 19 0.2× 36 729
Enrico Spera Italy 12 184 0.3× 148 0.3× 178 0.5× 73 0.4× 28 0.3× 19 512
M Pili Italy 9 269 0.4× 210 0.4× 78 0.2× 65 0.3× 22 0.2× 9 434

Countries citing papers authored by Ernst Ulbrich

Since Specialization
Citations

This map shows the geographic impact of Ernst Ulbrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernst Ulbrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernst Ulbrich more than expected).

Fields of papers citing papers by Ernst Ulbrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernst Ulbrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernst Ulbrich. The network helps show where Ernst Ulbrich may publish in the future.

Co-authorship network of co-authors of Ernst Ulbrich

This figure shows the co-authorship network connecting the top 25 collaborators of Ernst Ulbrich. A scholar is included among the top collaborators of Ernst Ulbrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernst Ulbrich. Ernst Ulbrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gittelman, Marc, et al.. (2010). The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. International Journal of Clinical Practice. 64(5). 594–603. 30 indexed citations
2.
3.
Gittelman, Marc, et al.. (2010). The POTENT II Randomised Trial: Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction. Journal of Men s Health. 7(3). 330–330. 14 indexed citations
4.
Ückert, Stefan, Katja Sigl, E. Waldkirch, et al.. (2009). Bedeutung von Phosphodiesteraseisoenzymen in der Kontrolle der humanen Detrusormuskulatur. Der Urologe. 48(7). 764–769. 12 indexed citations
5.
Ückert, Stefan, Peter Sandner, Ernst Ulbrich, Christian G. Stief, & Markus A. Kuczyk. (2009). IS THERE A ROLE OF THE PHOSPHODIESTERASE TYPE 5 (PDE5) IN THE CONTROL OF HUMAN DETRUSOR SMOOTH MUSCLE? A FUNCTIONAL AND MOLECULAR BIOLOGY STUDY. The Journal of Urology. 181(4S). 152–152. 8 indexed citations
6.
Porst, Hartmut, Peter Sandner, & Ernst Ulbrich. (2008). Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current Urology Reports. 9(4). 295–301.
7.
Stief, Christian G., Hartmut Porst, D. Neuser, Manfred Beneke, & Ernst Ulbrich. (2008). A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. European Urology. 53(6). 1236–1244. 216 indexed citations
8.
9.
Stief, Christian G., et al.. (2007). Vardenafil in the treatment of symptomatic benign prostatic hyperplasia. The Journal of Men s Health and Gender. 4(3). 375–375. 7 indexed citations
10.
Sandner, Peter, Hanna Tinel, Beatrix Stelte‐Ludwig, et al.. (2007). PDE5-Inhibitoren zur Behandlung des benignen Prostatasyndroms. Der Urologe. 46(9). 1189–1192. 1 indexed citations
11.
Stief, Christian G., Hartmut Porst, Thomas Evers, & Ernst Ulbrich. (2007). 1565: Vardenafil in the Treatment of Symptomatic Benign Prostatic Hyperplasia. The Journal of Urology. 177(4S). 517–517. 6 indexed citations
12.
Ulbrich, Ernst, et al.. (2004). Efficacy of Vardenafil in Men with Erectile Dysfunction: A Flexible-Dose Community Practice Study. European Urology. 46(1). 73–79. 31 indexed citations
13.
Stief, Christian G., H. Porst, I Sáenz de Tejada, Ernst Ulbrich, & Manfred Beneke. (2004). Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. International Journal of Clinical Practice. 58(3). 230–239. 65 indexed citations
14.
Brock, Gerald, Hartmut Porst, Christian G. Stief, et al.. (2004). 906: Influence of Prior Sildenafil Use on the Efficacy of Vardenafil in Men with Erectile Dysfunction: Retrospective Analysis of a Two Year Study. The Journal of Urology. 171(4S). 240–240. 2 indexed citations
15.
Montorsi, Francesco, Harin Padma-Nathan, Irène Buvat, et al.. (2004). Earliest Time to Onset of Action Leading to Successful Intercourse with Vardenafil Determined in an At-Home Setting: A Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Sexual Medicine. 1(2). 168–178. 42 indexed citations
16.
Ulbrich, Ernst, et al.. (2003). Under flexible dosing, “real world” conditions, vardenafil improved erectile function in a broad population of men. European Urology Supplements. 2(1). 96–96. 2 indexed citations
17.
Porst, H., R. Rosen, Harin Padma-Nathan, et al.. (2001). The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. International Journal of Impotence Research. 13(4). 192–199. 243 indexed citations
18.
Kropp, J., Marion Wencker, A. Hotze, et al.. (2001). Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency?. PubMed. 42(5). 744–51. 21 indexed citations
19.
Vogelmeier, Claus, et al.. (1997). The Intrapulmonary Half-Life and Safety of Aerosolized Alpha1-Protease Inhibitor in Normal Volunteers. American Journal of Respiratory and Critical Care Medicine. 155(2). 536–541. 33 indexed citations
20.
Ulbrich, Ernst & H. Nowak. (1990). Long-term multicentric study with azelastine in patients with intrinsic asthma.. PubMed. 40(11). 1225–30. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C C Carson Breakdown of academic impact, for papers by Fisseha Tesfaye Breakdown of academic impact, for papers by Richard Casey Breakdown of academic impact, for papers by Leslie Todd Breakdown of academic impact, for papers by Giuseppe Pera Breakdown of academic impact, for papers by Giulia Castagna Breakdown of academic impact, for papers by Yiming Yuan Breakdown of academic impact, for papers by Theodor Klotz Breakdown of academic impact, for papers by Enrico Spera Breakdown of academic impact, for papers by M Pili
Rankless by CCL
2026